RPG Life Sciences
RPG Life Sciences (RPGLS) is an Indian pharmaceutical company. Formerly known as Searle (India) Ltd, RPG Life Sciences is part of RPG Enterprises.[3] It has its corporate office in RPG House in Worli, Mumbai. Its three major activities are the manufacturing and marketing of bulk drugs, also known as API (active pharmaceutical ingredients); pharmaceutical formulation; and fermentation and biotechnology. RPGLS is present in the domestic as well as the international market. It exports its products primarily to Europe, Latin America, Australia and South East Asian countries.[4]
Public | |
Industry | Pharmaceuticals, biotechnology |
Founded | 1993 |
Headquarters | Mumbai, Maharashtra, India |
Key people | Yugal Sikri, Managing Director[1] |
Revenue | ₹376.30 crore (US$53 million) (2020)[2] |
Parent | RPG Enterprises |
Website | www.rpglifesciences.com |
History
Earlier known as Searle India Ltd, RPGLS started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to RPG Group. The company’s name was changed to RPG Life Sciences Ltd effective 1 April 1999. The company was in the business of pharmaceuticals and agrochemicals. It divested the agrochemicals business in 2001, as per the strategic decision to focus on pharmaceuticals, fermentation and biotechnology.
Business
RPGLS has a presence in healthcare, bio-technology, bulk drugs and generic businesses.
Three major activities of RPGLS are the manufacturing and marketing of bulk drugs (synthetic active pharmaceutical ingredients) and formulations internationally, pharmaceutical formulations and domestic marketing, and fermentation and biotechnology.
The healthcare division is divided into the Sertec and Acumed Speciality Divisions. The former manufactures medications for "critical and chronic" ailments, and the latter for chronic. The third division, Medillion, markets generic formulations. A separate laboratory with qualified people in chemical engineering and physical chemistry is provided to develop newer and more efficient formulations.
The biotechnology business mainly focuses on fermentation products. The fermentation division was set up in 1998 as a new arm of the company to exclusively cater to high-value life saving drugs produced by the fermentation route using biotechnology. The division has established itself in markets in India and overseas for its APIs and finished dosage forms. It exports its products to Brazil, Mexico, the Ukraine and Baltic States, the Dominican Republic, Peru, S. Korea, China, Chile and Argentina.
See also
References
- "RPG Life Sciences formulates growth plan". The Hindu Business Line. 13 July 2010. Retrieved 28 September 2010.
- "RPG Life Sciences - Audited Financial Result 2019-2020".
- "RPG Life Sciences eyes private equity placement". Hindustan Times. 27 July 2009. Retrieved 28 September 2010.
- Archived 30 June 2007 at the Wayback Machine